Cogent Biosciences completed submission of a New Drug Application (NDA) to the FDA for bezuclastinib in patients with gastrointestinal stromal tumors (GIST), representing a key regulatory milestone. The filing increases the probability of eventual approval and could drive single-digit percent stock movement upon FDA acceptance and subsequent review, with material commercial impact contingent on approval and market uptake.
Cogent Biosciences completed submission of a New Drug Application (NDA) to the FDA for bezuclastinib in patients with gastrointestinal stromal tumors (GIST), representing a key regulatory milestone. The filing increases the probability of eventual approval and could drive single-digit percent stock movement upon FDA acceptance and subsequent review, with material commercial impact contingent on approval and market uptake.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
